CT_and_pathologic_predictive_features_of_residual_mass_histologic_findings_after_chemotherapy_for_nonseminomatous_germ_cell_tumors:_can_residual_malignancy_or_teratoma_be_excluded?_Forty-eight_patients_with_disseminated_nonseminomatous_germ_cell_tumors_were_studied_retrospectively_to_determine_whether_initial_pathologic_features_and_pre-_and_post-chemotherapy_computed_tomographic_(CT)_features_could_be_used_to_exclude_malignancy_or_teratoma_in_residual_masses_that_were_excised_after_chemotherapy._Neither_CT_findings_(residual_mass_size,_attenuation,_and_degree_of_shrinkage_during_chemotherapy)_nor_type_of_primary_testicular_tumor_cell_was_significantly_correlated_with_malignancy_or_teratoma_versus_necrosis_in_residual_masses._No_significant_correlation_was_demonstrated_between_the_combined_features_of_(a)_the_absence_of_teratoma_in_a_histologic_specimen_of_the_primary_testicular_tumor_and_(b)_greater_than_90%_shrinkage_of_masses_during_chemotherapy_and_the_absence_of_malignancy_or_teratoma_in_residual_masses_as_suggested_in_the_literature._Of_nine_patients_with_both_of_these_findings,_two_had_malignancy_and_two_had_teratoma._Radiographic_and_pathologic_features_cannot_be_used_to_reliably_exclude_malignancy_or_teratoma_in_residual_abdominal_masses_after_chemotherapy_for_nonseminomatous_testicular_cancer.